Clinical Trials Logo

Nasal Surgical Procedures clinical trials

View clinical trials related to Nasal Surgical Procedures.

Filter by:
  • None
  • Page 1

NCT ID: NCT05273060 Recruiting - Clinical trials for Regenerative Medicine

Regenerative Medicine Approach to Nasal Reconstruction

Start date: May 18, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to gather information on the safety and effectiveness and compare nasal reconstruction standard planning versus 3D preoperative scanning/printing/planning.

NCT ID: NCT04194216 Enrolling by invitation - Nasal Obstruction Clinical Trials

Antibiotic Prophylaxis in Rhinoplasty

Start date: May 20, 2020
Phase: Phase 3
Study type: Interventional

This study compares the efficacy of a single intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides), alone versus both intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides) and postoperative oral dose of "cephalexin" or "clindamycin" use in nasal surgery.

NCT ID: NCT02822781 Completed - RHINOPLASTY Clinical Trials

Chronic Rhinosinusitis Classification Proposal

Start date: November 1, 2015
Phase: N/A
Study type: Observational

Chronic rhinosinusitis (CRS) is a debilitating disease that remains (smell, nasal patency, flow) because currently treatment protocols available to us are with a limited efficacy. The assessment of the response to surgical treatment protocols and monitoring the become of patients treated with only drugs should allow investigators to identify the predictive patient's profile for the response. With this prospective data, this study would allow investigators to make a classification of Chronic rhinosinusitis.

NCT ID: NCT02062996 Withdrawn - Dental Anesthesia Clinical Trials

Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption

Start date: June 2014
Phase: Phase 2
Study type: Interventional

Oxymetazoline is an α-adrenergic agonist that is commonly used as a topical sympathomimetic agent in over-the-counter decongestant sprays. It is used extensively at Nationwide Children's Hospital for surgical procedures to produce vasoconstriction and reduce bleeding. Although there is generally limited vascular absorption, when administered in larger doses, uptake of oxymetazoline can lead to significant systemic hemodynamic effects. The NCH anesthesia department recently reported a case of oxymetazoline induced postoperative hypertension in a three-year-old child following inferior turbinate reduction and adenoidectomy. Current practice at NCH is to soak pledgets with full strength oxymetazoline and insert a varying number of pledgets during surgical procedures or instill oxymetazoline drops into the nose prior to nasotracheal intubation. There is no pediatric data regarding the method of administration and the absorption of oxymetazoline or the dose-response relationship of oxymetazoline serum levels on blood pressure and heart rate. These studies would be the first to determine safe and appropriate doses of oxymetazoline in the pediatric population.